1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
VIA Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
10,279.00Market Cap
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
2.52
1.15
0.81
1.37
4.93
0.06
0.1
0.07
0.19
- -
- -
- -
- -
- -
Basic EPS, GAAP
-104.51
-37.24
-48.03
-50.42
-53.06
-49.6
-11.85
-17.46
-20.95
-2.24
-1.03
-1.05
- -
-0.47
Free Cash Flow per Basic Share
-9.27
-38.84
-42.08
-52.72
-47.66
-12.5
-11.61
-16.08
-19.07
-2.01
-0.97
-0.6
- -
-0.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-114.14
-122.03
-110.52
-150.88
-199.31
-123.44
-98.24
-93.59
-42.52
-4.15
-3.09
-4.09
- -
-4.48
Tangible Book Value per Share
-25.38
-8.83
100.88
80.81
26.84
4.06
12.82
9.34
-13.51
2.11
0.08
-0.56
- -
-0.91
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
1
1
- -
10
20
20
- -
20
Sales/Revenue/Turnover
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-3,986.61
-2,893.23
-6,355.79
-3,942.11
-1,036.76
-37,634.39
-12,229.53
-23,715.45
-9,868.14
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-8
-4
-10
-11
-12
-30
-10
-20
-9
-22
-20
-21
-10
-10
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4,140.61
-3,239.95
-5,940.51
-3,687.27
-1,075.79
-87,576.02
-12,458.42
-23,684.31
-10,352.31
- -
- -
- -
- -
- -
Working Capital
-1
- -
20
15
2
7
23
27
-6
20
1
-11
-19
-19
LT Debt
- -
- -
1
1
1
4
11
16
- -
- -
- -
- -
- -
- -
Total Equity
-2
-1
20
18
6
2
11
11
-6
21
2
-11
-18
-18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
ST Debt
11
13
14
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
2
2
1

Working Capital

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
15
17
19
Payables & Accruals
4
5
5
ST Debt
11
13
14
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-124.06%
-289.76%
65.18%
Free Cash Flow
10.57%
-1.53%
-48.59%
Net Income, GAAP
23.95%
7.78%
-54.23%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.3
-0.26
-0.25
- -
-1.03
2009
-0.22
-0.22
-0.4
- -
-1.05
2010
-0.14
-0.1
-0.1
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Thomas Quertermous
Full Time Employees
6
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
750 Battery Street San Francisco CA United States of America
IPO Date
Jun 6, 2007
Website
viapharmaceuticals.com
Similar Companies
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ)
Pharmaids Pharmaceuticals Limited (PHARMAID.BO)
Astena Holdings Co., Ltd. (8095.T)
Wockhardt Limited (WOCKPHARMA.NS)
EastWest Bioscience Inc. (HBOSF)
Sibannac, Inc. (SNNC)
Business
VIA Pharmaceuticals, Inc. (VIAP) is a development-stage biotechnology company focused on developing small-molecule drugs targeting vascular inflammation and other underlying causes of cardiovascular and metabolic diseases, including atherosclerosis, high cholesterol, high triglycerides, insulin sensitization, and type 2 diabetes; its pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor beta agonist for dyslipidemia such as elevated LDL cholesterol, triglycerides, and Lp(a), a preclinical diacylglycerol acyl transferase 1 (DGAT1) inhibitor for type 2 diabetes with potential in weight control and dyslipidemia, and VIA-2291 (atreleuton), a 5-lipoxygenase inhibitor that completed Phase 2 trials for atherosclerotic plaque reduction. Founded in 2004 by Thomas Quertermous, Adeoye Y. Olukotun, and Douglass B. Given, the company is headquartered at 750 Battery Street, Suite 330, San Francisco, California, and operates primarily in the United States with research, development, and commercialization agreements including those with Hoffman-La Roche Inc. and Hoffman-La Roche Ltd. for THR beta agonists and DGAT1 compounds. While no major acquisitions, funding rounds, partnerships, or new product launches have been reported in the last 1-2 years, the company maintains its pipeline focus amid a history of strategic restructurings, such as the 2007 merger with Corautus Genetics and earlier financing arrangements, and trades on the OTC Pink Sheets market.